menu
    • menu
    [{"orgOrder":0,"company":"Eva Pharma","sponsor":"MARC-CRO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"EGYPT","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rotigexole","moa":"D2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ MARC-CRO","highestDevelopmentStatusID":"1","companyTruncated":"Eva Pharma \/ MARC-CRO"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"EGYPT","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"EGYPT","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Nephrology","graph2":"Phase III","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"MARC-CRO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Neurology","graph2":"Phase IV","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ MARC-CRO","highestDevelopmentStatusID":"11","companyTruncated":"Eva Pharma \/ MARC-CRO"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"EGYPT","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"SARS coronavirus 3C-like proteinase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Egyvax Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Gleptomet","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Revemact","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Eva Pharma

    Menu

    Eva Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rotigexole

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : MARC-CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adhesion and Safety of Rotigexole Compared to Neupro®

                            Details : Rotigexole is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 11, 2025

                            Lead Product(s) : Rotigexole

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : MARC-CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lilly, EVA Pharma Announce Regulatory Approval for Locally Manufactured Insulin

                            Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.

                            Product Name : Humalog

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenacapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

                            Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

                            Product Name : Sunlenca

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : Lenacapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly, EVA Pharma Collaborate To Expand Baricitinib Access in Low-Income Nations

                            Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.

                            Product Name : Olumiant

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 04, 2024

                            Lead Product(s) : Baricitinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha Lipoic Acid

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : Ain Shams University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alpha Lipoic Acid in Pediatrics on Hemodialysis

                            Details : Alpha-lipoic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : Alpha Lipoic Acid

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : Ain Shams University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha Lipoic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : MARC-CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Eg...

                            Details : Alpha-lipoic acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Neuropathies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2023

                            Lead Product(s) : Alpha Lipoic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : MARC-CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gleptomet

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet...

                            Details : Gleptomet is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : Gleptomet

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus P...

                            Details : Nirmatrelvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2022

                            Lead Product(s) : Nirmatrelvir

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Egyvax Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection

                            Details : Egyvax Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 01, 2022

                            Lead Product(s) : Egyvax Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Eva Pharma

                            Egypt arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metformin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Recipient : Alexandria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-diabetic Drugs and Fatty Liver Management

                            Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2021

                            Lead Product(s) : Metformin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Recipient : Alexandria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth